See the DrugPatentWatch profile for trodelvy
Common Side Effects Patients Report with Trodelvy
Trodelvy (sacituzumab govitecan) commonly causes neutropenia (low white blood cells, affecting 61-72% of patients), anemia (36-63%), diarrhea (51-64%), nausea (47-64%), and fatigue (41-51%). These often require dose adjustments or supportive care like growth factors for neutropenia.[1][2]
Serious Risks and Warnings
The drug carries black box warnings for severe neutropenia and severe diarrhea, which can lead to sepsis or hospitalization. Other severe risks include:
- Febrile neutropenia (up to 8%).
- Pneumonitis (lung inflammation, 1-2%, sometimes fatal).
- Hyperglycemia (high blood sugar).
- Decreased platelet count (thrombocytopenia, 18-27%).
Infusion reactions occur in 8-13%, sometimes severe.[1][2][3]
How Trodelvy Causes These Risks
Trodelvy is an antibody-drug conjugate releasing SN-38 (active topoisomerase inhibitor) inside cancer cells. Off-target release in healthy tissues, especially the gut and bone marrow, drives neutropenia and diarrhea. Hepatic impairment worsens exposure to SN-38, increasing toxicity.[2][3]
Risks in Specific Patient Groups
Patients with moderate liver issues face higher SN-38 levels and toxicity risks—avoid use if bilirubin exceeds 1.5x upper normal limit. Elderly patients (>65) see more frequent severe neutropenia (72% vs. 51%). No data supports use in pregnancy (embryo-fetal toxicity risk); effective contraception is required.[1][2]
Monitoring and Management During Treatment
Blood counts must be checked before each dose; hold or reduce for grade 3-4 neutropenia. Diarrhea needs loperamide prophylaxis and escalation to IV fluids if severe. Premedicate with diphenhydramine and acetaminophen for infusions. Discontinue for recurrent severe issues.[2][3]
How Trodelvy Risks Compare to Alternatives
Compared to chemotherapy like eribulin or capecitabine (used in metastatic triple-negative breast cancer), Trodelvy shows higher neutropenia (72% vs. 30-50%) but better progression-free survival in trials. Antibody-drug conjugates like Enhertu have similar profiles but target different cancers.[3][4]
[1]: Trodelvy Prescribing Information, Gilead Sciences, https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvypi.pdf
[2]: FDA Label for Sacituzumab Govitecan, https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/761115s000lbl.pdf
[3]: ASCO Post on Trodelvy Safety Profile, https://ascopost.com/news/july-2020/metastatic-triple-negative-breast-cancer-fda-approves-sacituzumab-govitecan/
[4]: ASCENT Trial Data (NEJM 2021), https://www.nejm.org/doi/full/10.1056/NEJMoa2028485